RecruitingNCT07420283
Adding brenipatide or placebo to buprenorphine with or without naloxone for opioid use
About this title
A Study of Brenipatide in Participants With Opioid Use Disorder
Read the official source — NCT07420283Medication studyAges 18–75Multiple countriesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 75 years.
- Listed locations
- Phoenix and 60 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 13, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 465
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada, United Kingdom
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT07420283
- Official title
Show the full official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study With a Separate Open-label Cohort to Evaluate the Efficacy and Safety of Brenipatide as Adjunctive Treatment to Transmucosal Buprenorphine With or Without Naloxone in Early Recovery of Participants With Opioid Use Disorder (RENEW-Op-1)
Recruitment & locations
RecruitingPhoenix, United States · Little Rock, United States · Fountain Valley, United States
48 more locations
- San Francisco, United States
- Bradenton, United States
- Daytona Beach, United States
- Hollywood, United States
- Lakeland, United States
- Miami, United States
- Naples, United States
- Port Charlotte, United States
- Tampa, United States
- West Palm Beach, United States
- Chicago, United States
- Indianapolis, United States
- Lexington, United States
- Baltimore, United States
- Rockville, United States
- Boston, United States
- Watertown, United States
- Ridgeland, United States
- New York, United States
- The Bronx, United States
- Columbus, United States
- Oklahoma City, United States
- Philadelphia, United States
- Providence, United States
- Sioux Falls, United States
- DeSoto, United States
- Houston, United States
- Charlottesville, United States
- Roanoke, United States
- Seattle, United States
- Calgary, Canada
- Courtice, Canada
- Kamloops, Canada
- Kelowna, Canada
- Kingston, Canada
- Mississauga, Canada
- Toronto, Canada
- Guaynabo, Puerto Rico
- Chertsey, United Kingdom
- Doncaster, United Kingdom
- Eastbourne, United Kingdom
- Glasgow, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
- Milton Keynes, United Kingdom
- Southampton, United Kingdom
- Uxbridge, United Kingdom
- Wolverhampton, United Kingdom
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Does this study involve medication?
Yes. The study involves medication, including Brenipatide, Placebo and Buprenorphine.
Who can participate?
Listed age limits: 18 years to 75 years.
Is this study still recruiting?
The registry lists this study as recruiting.
